Agreement signed between Panacea Biotec and Serum Institute of India

Panacea Biotec Ltd. (PBL), India's leading biopharmaceutical company and one of the largest vaccine manufacturers, has signed two long-term collaboration agreements with Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer and SII's wholly owned subsidiary, Bilthovan Biologicals BV (BBIO).

Under the collaboration agreement, SII is entitled to manufacture and sell the all-cell whole-cell pertussis vaccine (WP) and Hexavalent Vaccine (DTwP-HepB-Hib-IPV) based on the Injectable Polio Vaccine ) based on Salk, developed and marketed by PBL, the first of its kind in this category.
  • SII will ensure the delivery of bulk BTI to PBL, an important component of the Hexavalent vaccine, from its wholly-owned subsidiary BBIO Netherlands which has technology to produce BTI, which previously only three other vaccine manufacturers in the world owned.
  • Over the next two years both SII and PBL will work together to obtain this Hexavalent wP-IPV vaccine introduced in the National Immunization Program of the Government of India and developing countries, working closely with key stakeholders including , among others, national
  • governments, WHO, GAVI, BMGF and other UN agencies, etc.

Dr. Rajesh Jain , Joint Managing Director, PBL, said that millions of children in developing countries with an annual birth cohort of approximately 121 million will have easy access to a fully liquid Hexavalent vaccine containing six very important antigens to protect against six feared diseases , such as diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenza type B and poliomyelitis.

It is estimated that global demand for IPV / IPV-containing vaccines will increase significantly from ~ 100 million by 2020, until when supply constraints will continue, to 250-350 million doses each year from 2022, depending on a timeline of two or three doses, as the Strategic Advisory Group of Experts (SAGE) in Immunization recommended in April 2017 at least 2 doses of IPV in the routine immunization schedule of the countries after OPV withdrawal.

Due to IPV's global supply restriction since 2015, only 52% of the projected supply has been delivered to UN agencies. Thus, 18 countries were unable to introduce BTI into their immunization and 15 of 70 countries eligible for BTI approved for GAVI support had to discontinue immunization.

Mr. Adar C. Poonawalla, CEO and Executive Director, SII, said: "It is a landmark agreement in which two major Indian vaccine companies have come together to meet the unmet needs of both the private and the public markets worldwide. the convenience of the 'six in one' there is the potential of more than 250 million doses in the next 3-4 years with a market of over $ 1.25 billion per year. "

Mr. RK Suri, Senior Advisor, who orchestrated the mega agreement between two major players in the vaccine market, said: "It marks the beginning of a new era in the vaccine area and announces a new business model, 'Collaborate and Compete' ".

Read Similar Articles

0 Comments Write your comment

    1. Loading...